MEDIA ADVISORY: UCI Law to Host 7th Annual Intellectual Property Law Conference: "Biosimilar Innovation"
IRVINE, Calif. (Feb. 5, 2019) – The University of California, Irvine School of Law will host its annual intellectual property law conference featuring expert panels discussing “Biosimilar Innovation." The conference will be livestreamed, and a video recording will be available following the event.

WHEN: Friday, Feb. 8, 2019, 8:30 a.m. to 5:00 p.m. PT.

WHERE: UC Irvine School of Law, MPAA 420 (map and directions) .

WHAT: Biosimilar medical products offer the promise of enhanced medical therapies at sustainable pricing. However, the scientific and economic challenges associated with biosimilars threaten to impede the promise of such medical advances. New incentive strategies are needed to advance development in this area.
To address such challenges, speakers at this conference will explore the legal and regulatory frameworks needed to encourage innovative development and distribution of biosimilar products.

WHO: Led by UCI Chancellor's Professor of Law Dan Burk , the schedule includes the following panelists and sessions:

8:45 a.m. Welcome
9:00-10:20 a.m.                     
Panel 1: Biosimilar Patenting
  • Nicholson Price II, University of Michigan
“Patent Thickets in Biologic Manufacturing”

  • Dan L. Burk, UC Irvine
“Structure and Function in Biomolecular Obviousness”

10:20-10:40 a.m. Morning Break

10:40 a.m.-12:00 p.m.          
Panel 2: Regulatory Perspectives
  • Michael Carrier, Rutgers University, Camden
“Antitrust and Biosimilars: What’s New and What’s Not”
  • Jordan Paradise, Loyola University Chicago
“FDA Oversight of Biosimilars”

12:00-1:30 p.m. Lunch

1:30-2:50 p.m.                      
Panel 3: Comparative Perspectives
  • Ariel Stern, Harvard Business School
“The Impact of the Entry of Biosimilars: Evidence from Europe"

  • Timo Minssen, University of Copenhagen
“The Proposed EU IP Exception for Generics & Biosimilars Exports – A Cure Worse Than the Disease?”

2:50-3:10 p.m. Afternoon Break

3:10-4:30 p.m.                      
Panel 4: Scouting the Path Ahead
  • Brenda Simon, Thomas Jefferson Law School
“Patent Eligibility of Biologic and Biosimilar Inventions: A Doctrine in Flux”
  • Jacob Sherkow, New York Law School
“Form Follows Function: Proper Antibody Patents After Amgen v. Sanofi

4:45 Adjourn

For more information about the conference, including speaker biographies and paper abstracts, please click here .

REGISTRATION: To register to attend the event in person, click here.


Colleen Taricani
Assistant Dean for Communications , (949) 824-3063

Ryne Hodkowski
Public Relations Manager , (949) 824-0385